The immune system constantly scans the body for tumor cells, destroying most of them before they can become a detectable cancer, but sometimes it needs a boost. That’s the thinking behind the new generation of cancer treatments called immunotherapies. One of the most promising versions are CAR-Ts (chimeric antigen receptor T cells).

Two CAR-Ts have been approved by the Food and Drug Administration: Yescarta, developed Kite Pharma (which was bought by Gilead), is used to treat adult patients with certain types of large B-cell lymphoma, and Kymriah, from Novartis, is for a form of acute lymphoblastic leukemia.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • I am a big fan of Sharon Begley. I try to read everything by her that I come across. But – subscribe to Stat Plus would just add more emails that I don’t have time to read. I read Megan five days a week, and I often read articles she recommends, but I also read a great many other things and Medicine is not my primary interest. Please don’t do this again. I know you want in increase Stat Plus’ members but please understand that everyone’s time is limited.
    Thank you,
    Norma Frank

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy